Methylation of PCDH19 predicts poor prognosis of hepatocellular carcinoma

• DOI: 10.1111/ajco.12982
• Publication Date: 2018-05-11T08:09:18Z
• Authors: Ting Zhang; Guiwen Guan; Tingting Chen; Jingling Jin; Lichun Zhang; Mingjie Yao; Xuewei Qi; Jun Zou; Jiacheng Chen; Fengmin Lu; Xiangmei Chen
• Keywords: Male; 0301 basic medicine; Carcinoma, Hepatocellular; Liver Neoplasms; Down-Regulation; DNA Methylation; Middle Aged; Cadherins; Prognosis; Protocadherins; 3. Good health; 03 medical and health sciences; Biomarkers, Tumor; Humans; CpG Islands; Female; Promoter Regions, Genetic

Abstract Objective Several members of protocadherins (PCDHs) have been identified as tumor suppressor genes in human carcinogenesis, but little is known about PCDH19. The aim the present study was to assess expression and methylation PCDH19 hepatocellular carcinoma (HCC). Methods RNA‐seq data from Cancer Genome Atlas Database were downloaded used for analyzing HCC patients normal liver tissues. We collected 63 paired nontumor tissues hepatitis B virus‐related patients. detected by real‐time quantitative RT‐PCR assay. gene analyzed DNA methylation‐sensitive endonuclease digestion sequential PCR. prognostic value evaluated Kaplan–Meier analyses. Results downregulated seven cell lines compared PCHD19 promoter frequently hypermethylated three (SMMC7721, Hep3B SNU387) 5‐aza‐dC treatment could significantly increased these methylated cells. In addition, exhibited hypermethylation both frequency (30.15% vs 9.52%, P = 0.003) intensity ( 0.002) that Kaplan‐Meier survival analysis revealed correlated with poor overall Conclusion HCC, which mediated at least part hypermethylation. might a potential marker